Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymph Node Excision | 1 | 2017 | 4 | 0.530 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2017 | 3 | 0.530 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2017 | 4 | 0.530 |
Why?
|
| Lymph Nodes | 1 | 2017 | 10 | 0.530 |
Why?
|
| Middle Aged | 6 | 2020 | 1775 | 0.210 |
Why?
|
| Aged | 6 | 2020 | 1860 | 0.210 |
Why?
|
| Male | 8 | 2020 | 3399 | 0.190 |
Why?
|
| Female | 8 | 2020 | 3346 | 0.190 |
Why?
|
| Humans | 11 | 2020 | 5837 | 0.190 |
Why?
|
| State Medicine | 1 | 2002 | 2 | 0.190 |
Why?
|
| National Health Programs | 1 | 2002 | 2 | 0.190 |
Why?
|
| Family Practice | 1 | 2002 | 6 | 0.180 |
Why?
|
| Adult | 6 | 2017 | 1670 | 0.180 |
Why?
|
| Survival Rate | 2 | 2018 | 60 | 0.160 |
Why?
|
| Esophageal pH Monitoring | 1 | 2020 | 1 | 0.160 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 6 | 0.160 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 29 | 0.150 |
Why?
|
| beta-Thalassemia | 2 | 2010 | 2 | 0.150 |
Why?
|
| Hydroxyurea | 2 | 2010 | 3 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 22 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 59 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 7 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 10 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 14 | 0.130 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 1 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2017 | 4 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 7 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 1 | 0.130 |
Why?
|
| Fundoplication | 1 | 2017 | 4 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 74 | 0.130 |
Why?
|
| Operative Time | 1 | 2017 | 17 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 24 | 0.130 |
Why?
|
| Laparoscopy | 1 | 2017 | 47 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2017 | 53 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 333 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2017 | 75 | 0.120 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2013 | 1 | 0.100 |
Why?
|
| Trigonella | 1 | 2013 | 1 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2013 | 2 | 0.100 |
Why?
|
| Levodopa | 1 | 2013 | 6 | 0.100 |
Why?
|
| Operating Rooms | 1 | 2012 | 2 | 0.090 |
Why?
|
| Noise, Occupational | 1 | 2012 | 2 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 10 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2013 | 134 | 0.080 |
Why?
|
| Hemoglobin E | 1 | 2010 | 1 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2010 | 13 | 0.080 |
Why?
|
| Young Adult | 3 | 2017 | 421 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 411 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2002 | 1 | 0.050 |
Why?
|
| Australia | 1 | 2002 | 4 | 0.050 |
Why?
|
| United Kingdom | 1 | 2002 | 11 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2002 | 12 | 0.050 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2000 | 2 | 0.040 |
Why?
|
| Multimedia | 1 | 2020 | 2 | 0.040 |
Why?
|
| Comprehension | 1 | 2020 | 8 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 26 | 0.040 |
Why?
|
| Mutation | 2 | 2010 | 101 | 0.040 |
Why?
|
| Child | 2 | 2010 | 339 | 0.030 |
Why?
|
| Cardia | 1 | 2018 | 1 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 8 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 4 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 15 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2018 | 7 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 16 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 15 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 15 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2018 | 11 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 3 | 0.030 |
Why?
|
| Adolescent | 2 | 2010 | 488 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 54 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 37 | 0.030 |
Why?
|
| New York City | 1 | 2017 | 1 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 14 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2010 | 601 | 0.030 |
Why?
|
| United States | 1 | 2018 | 502 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2017 | 584 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 1034 | 0.030 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2013 | 1 | 0.020 |
Why?
|
| Seeds | 1 | 2013 | 1 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 78 | 0.020 |
Why?
|
| Extracorporeal Circulation | 1 | 2012 | 1 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2012 | 5 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2012 | 3 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2012 | 5 | 0.020 |
Why?
|
| Ferritins | 1 | 2010 | 1 | 0.020 |
Why?
|
| beta-Globins | 1 | 2010 | 1 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2010 | 3 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 51 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 114 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2009 | 1 | 0.020 |
Why?
|
| India | 1 | 2009 | 3 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hematology | 1 | 2009 | 2 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 19 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 87 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 66 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 174 | 0.020 |
Why?
|
| Pakistan | 1 | 2000 | 1 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2000 | 30 | 0.010 |
Why?
|